[
  {
    "account_name": "AstraZeneca",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 22.850412159168872,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | trial_collaborator: Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | trial_collaborator: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
    "best_fit_trial_title": "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04257578",
    "best_urgency_trial_title": "A Study of AZD0120 in Autoimmune Diseases",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07295847",
    "sec": {
      "recent_total": 5,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": "2026-02-10T00:00:00+00:00",
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "AstraZeneca",
    "total_score": 22.850412159168872,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07215585",
      "https://clinicaltrials.gov/study/NCT07295847",
      "https://clinicaltrials.gov/study/NCT06542250",
      "https://www.sec.gov/Archives/edgar/data/901832/000165495426001073/a3234s.htm",
      "https://clinicaltrials.gov/study/NCT06897930",
      "https://clinicaltrials.gov/study/NCT07391657",
      "https://clinicaltrials.gov/study/NCT06564038",
      "https://clinicaltrials.gov/study/NCT07224373"
    ],
    "score_details": {
      "trial_count": 20,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 1
  },
  {
    "account_name": "Chongqing Precision Biotech Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 21.039636039929274,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus | trial_collaborator: Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors | trial_collaborator: A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors",
    "best_fit_trial_title": "Study of CD19 CAR-T Therapy for Refractory SLE",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07403097",
    "best_urgency_trial_title": "Study of CD19 CAR-T Therapy for Refractory SLE",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07403097",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Chongqing Precision Biotech Co., Ltd",
    "total_score": 21.039636039929274,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07403097",
      "https://clinicaltrials.gov/study/NCT06222853",
      "https://clinicaltrials.gov/study/NCT07318259",
      "https://clinicaltrials.gov/study/NCT06821048",
      "https://clinicaltrials.gov/study/NCT07331467",
      "https://clinicaltrials.gov/study/NCT06892145",
      "https://clinicaltrials.gov/study/NCT07250386",
      "https://clinicaltrials.gov/study/NCT07247396"
    ],
    "score_details": {
      "trial_count": 36,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-11T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 2
  },
  {
    "account_name": "Yake Biotechnology Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.924432846120883,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia | trial_collaborator: A Multicenter Study of CAR-T Cells in Primary Ph+All | trial_collaborator: Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia",
    "best_fit_trial_title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07370064",
    "best_urgency_trial_title": "Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07370064",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Yake Biotechnology Ltd.",
    "total_score": 20.924432846120883,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07370064",
      "https://clinicaltrials.gov/study/NCT07252336",
      "https://clinicaltrials.gov/study/NCT07144020",
      "https://clinicaltrials.gov/study/NCT05827835",
      "https://clinicaltrials.gov/study/NCT06836505",
      "https://clinicaltrials.gov/study/NCT06793241",
      "https://clinicaltrials.gov/study/NCT06787560",
      "https://clinicaltrials.gov/study/NCT06785519"
    ],
    "score_details": {
      "trial_count": 31,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-27T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 3
  },
  {
    "account_name": "Regeneron Pharmaceuticals",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.906915551506973,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients Wi | trial_collaborator: Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relap | trial_collaborator: PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML",
    "best_fit_trial_title": "PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05105152",
    "best_urgency_trial_title": "A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05092347",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Regeneron Pharmaceuticals",
    "total_score": 20.906915551506973,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05092347",
      "https://clinicaltrials.gov/study/NCT03761108",
      "https://clinicaltrials.gov/study/NCT05828511",
      "https://clinicaltrials.gov/study/NCT06230224",
      "https://clinicaltrials.gov/study/NCT06097364",
      "https://clinicaltrials.gov/study/NCT06091865",
      "https://clinicaltrials.gov/study/NCT06149286",
      "https://clinicaltrials.gov/study/NCT06469281"
    ],
    "score_details": {
      "trial_count": 24,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-12T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 4
  },
  {
    "account_name": "Janssen Research & Development, LLC",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.85041215425066,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleuce | trial_collaborator: Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | trial_collaborator: MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma",
    "best_fit_trial_title": "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04923893",
    "best_urgency_trial_title": "A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05022849",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Janssen Research & Development, LLC",
    "total_score": 20.85041215425066,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04923893",
      "https://clinicaltrials.gov/study/NCT05022849",
      "https://clinicaltrials.gov/study/NCT05421663",
      "https://clinicaltrials.gov/study/NCT04181827",
      "https://clinicaltrials.gov/study/NCT06550895",
      "https://clinicaltrials.gov/study/NCT05784441",
      "https://clinicaltrials.gov/study/NCT07149857",
      "https://clinicaltrials.gov/study/NCT04557098"
    ],
    "score_details": {
      "trial_count": 20,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 5
  },
  {
    "account_name": "Kite, A Gilead Company",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.841397625398624,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | trial_collaborator: Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond | trial_collaborator: Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL",
    "best_fit_trial_title": "Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07375628",
    "best_urgency_trial_title": "Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05396885",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Kite, A Gilead Company",
    "total_score": 20.841397625398624,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05396885",
      "https://clinicaltrials.gov/study/NCT04155749",
      "https://clinicaltrials.gov/study/NCT06144606",
      "https://clinicaltrials.gov/study/NCT06539338",
      "https://clinicaltrials.gov/study/NCT06413498",
      "https://clinicaltrials.gov/study/NCT07375628",
      "https://clinicaltrials.gov/study/NCT07304154",
      "https://clinicaltrials.gov/study/NCT06079164"
    ],
    "score_details": {
      "trial_count": 20,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-11T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 6
  },
  {
    "account_name": "CARsgen Therapeutics Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.73569781941687,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC | trial_collaborator: A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell  | trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",
    "best_fit_trial_title": "A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07339332",
    "best_urgency_trial_title": "Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07031713",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "CARsgen Therapeutics Co., Ltd.",
    "total_score": 20.73569781941687,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07355972",
      "https://clinicaltrials.gov/study/NCT07339332",
      "https://clinicaltrials.gov/study/NCT07031713",
      "https://clinicaltrials.gov/study/NCT06730256",
      "https://clinicaltrials.gov/study/NCT06822881",
      "https://clinicaltrials.gov/study/NCT06988059",
      "https://clinicaltrials.gov/study/NCT07033299",
      "https://clinicaltrials.gov/study/NCT04581473"
    ],
    "score_details": {
      "trial_count": 19,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-21T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 7
  },
  {
    "account_name": "Novartis Pharmaceuticals",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.719793721157956,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lympho | trial_collaborator: RadiothErapy priMIng for CAR-T",
    "best_fit_trial_title": "CAR-T Long Term Follow Up (LTFU) Study",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT02445222",
    "best_urgency_trial_title": "Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06704269",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Novartis Pharmaceuticals",
    "total_score": 20.719793721157956,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06704269",
      "https://clinicaltrials.gov/study/NCT06665256",
      "https://clinicaltrials.gov/study/NCT05460533",
      "https://clinicaltrials.gov/study/NCT07048197",
      "https://clinicaltrials.gov/study/NCT06617793",
      "https://clinicaltrials.gov/study/NCT03960840",
      "https://clinicaltrials.gov/study/NCT03570892",
      "https://clinicaltrials.gov/study/NCT06785818"
    ],
    "score_details": {
      "trial_count": 15,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-05T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 8
  },
  {
    "account_name": "Pfizer",
    "fit": 4.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.6972052435467,
    "fit_reason": "molecule match: elranatamab",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guide | trial_collaborator: Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | trial_collaborator: A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elra",
    "best_fit_trial_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06215118",
    "best_urgency_trial_title": "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06215118",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Pfizer",
    "total_score": 20.6972052435467,
    "fit_score": 4.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06215118",
      "https://clinicaltrials.gov/study/NCT05748171",
      "https://clinicaltrials.gov/study/NCT05623020",
      "https://clinicaltrials.gov/study/NCT06152575",
      "https://clinicaltrials.gov/study/NCT05020236",
      "https://clinicaltrials.gov/study/NCT06057402",
      "https://clinicaltrials.gov/study/NCT05675449",
      "https://clinicaltrials.gov/study/NCT06974786"
    ],
    "score_details": {
      "trial_count": 14,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-05T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 9
  },
  {
    "account_name": "Kyverna Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.67354704740634,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2,PHASE3)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple  | trial_collaborator: CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | trial_collaborator: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Prog",
    "best_fit_trial_title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2,PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06193889",
    "best_urgency_trial_title": "KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2,PHASE3",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06193889",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Kyverna Therapeutics",
    "total_score": 20.67354704740634,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07403188",
      "https://clinicaltrials.gov/study/NCT06193889",
      "https://clinicaltrials.gov/study/NCT06451159",
      "https://clinicaltrials.gov/study/NCT06588491",
      "https://clinicaltrials.gov/study/NCT06342960",
      "https://clinicaltrials.gov/study/NCT05938725",
      "https://clinicaltrials.gov/study/NCT06400303",
      "https://clinicaltrials.gov/study/NCT06152172"
    ],
    "score_details": {
      "trial_count": 12,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-11T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 10
  },
  {
    "account_name": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.66907867960382,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engine | trial_collaborator: BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | trial_collaborator: A Trial of \"Armored\" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies",
    "best_fit_trial_title": "Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06297226",
    "best_urgency_trial_title": "A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06220201",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
    "total_score": 20.66907867960382,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06220201",
      "https://clinicaltrials.gov/study/NCT06615479",
      "https://clinicaltrials.gov/study/NCT06297226",
      "https://clinicaltrials.gov/study/NCT07015983",
      "https://clinicaltrials.gov/study/NCT07335562",
      "https://clinicaltrials.gov/study/NCT07115745",
      "https://clinicaltrials.gov/study/NCT05869955",
      "https://clinicaltrials.gov/study/NCT06121843"
    ],
    "score_details": {
      "trial_count": 12,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-10T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 11
  },
  {
    "account_name": "Miltenyi Biomedicine GmbH",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.638989955364195,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblas | trial_collaborator: The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR ",
    "best_fit_trial_title": "CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07361029",
    "best_urgency_trial_title": "CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07361029",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Miltenyi Biomedicine GmbH",
    "total_score": 20.638989955364195,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07361029",
      "https://clinicaltrials.gov/study/NCT07288879",
      "https://clinicaltrials.gov/study/NCT04844866",
      "https://clinicaltrials.gov/study/NCT06424340",
      "https://clinicaltrials.gov/study/NCT06508931",
      "https://clinicaltrials.gov/study/NCT06189157",
      "https://clinicaltrials.gov/study/NCT06508775",
      "https://clinicaltrials.gov/study/NCT03853616"
    ],
    "score_details": {
      "trial_count": 14,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-22T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 12
  },
  {
    "account_name": "Guangzhou Bio-gene Technology Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.626565111293143,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML | trial_collaborator: Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Soli | trial_collaborator: A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus",
    "best_fit_trial_title": "Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07338357",
    "best_urgency_trial_title": "Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06118788",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Guangzhou Bio-gene Technology Co., Ltd",
    "total_score": 20.626565111293143,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07338357",
      "https://clinicaltrials.gov/study/NCT07196124",
      "https://clinicaltrials.gov/study/NCT07196111",
      "https://clinicaltrials.gov/study/NCT07195617",
      "https://clinicaltrials.gov/study/NCT07152236",
      "https://clinicaltrials.gov/study/NCT07152210",
      "https://clinicaltrials.gov/study/NCT07152223",
      "https://clinicaltrials.gov/study/NCT06118788"
    ],
    "score_details": {
      "trial_count": 15,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 13
  },
  {
    "account_name": "Hebei Senlang Biotechnology Inc., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.61060975065365,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | trial_collaborator: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL | trial_collaborator: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL",
    "best_fit_trial_title": "SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07234721",
    "best_urgency_trial_title": "Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07244380",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Hebei Senlang Biotechnology Inc., Ltd.",
    "total_score": 20.61060975065365,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07234721",
      "https://clinicaltrials.gov/study/NCT07244380",
      "https://clinicaltrials.gov/study/NCT07244406",
      "https://clinicaltrials.gov/study/NCT07161193",
      "https://clinicaltrials.gov/study/NCT05618041",
      "https://clinicaltrials.gov/study/NCT05388695",
      "https://clinicaltrials.gov/study/NCT06880913",
      "https://clinicaltrials.gov/study/NCT06874946"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-10T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 14
  },
  {
    "account_name": "Bristol-Myers Squibb",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.59073408403082,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Study of BMS-986453 in Newly Diagnosed Multiple Myeloma | trial_collaborator: CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis | trial_collaborator: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients ",
    "best_fit_trial_title": "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04205409",
    "best_urgency_trial_title": "Study of BMS-986453 in Newly Diagnosed Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07333261",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bristol-Myers Squibb",
    "total_score": 20.59073408403082,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07333261",
      "https://clinicaltrials.gov/study/NCT07388277",
      "https://clinicaltrials.gov/study/NCT06215118",
      "https://clinicaltrials.gov/study/NCT06523621",
      "https://clinicaltrials.gov/study/NCT04205409",
      "https://clinicaltrials.gov/study/NCT06209619",
      "https://clinicaltrials.gov/study/NCT05621096",
      "https://clinicaltrials.gov/study/NCT04003649"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 15
  },
  {
    "account_name": "Genentech, Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.580043566756437,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lym | trial_collaborator: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MC | trial_collaborator: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Agg",
    "best_fit_trial_title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05633615",
    "best_urgency_trial_title": "A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06984341",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Genentech, Inc.",
    "total_score": 20.580043566756437,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06984341",
      "https://clinicaltrials.gov/study/NCT05633615",
      "https://clinicaltrials.gov/study/NCT06357676",
      "https://clinicaltrials.gov/study/NCT07008378",
      "https://clinicaltrials.gov/study/NCT05464329",
      "https://clinicaltrials.gov/study/NCT05260957",
      "https://clinicaltrials.gov/study/NCT05801939",
      "https://clinicaltrials.gov/study/NCT06252675"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-03T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 16
  },
  {
    "account_name": "Rui Therapeutics Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.559633612235174,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of R | trial_collaborator: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm | trial_collaborator: RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies",
    "best_fit_trial_title": "An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07241468",
    "best_urgency_trial_title": "RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07105735",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Rui Therapeutics Co., Ltd",
    "total_score": 20.559633612235174,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07241468",
      "https://clinicaltrials.gov/study/NCT07246096",
      "https://clinicaltrials.gov/study/NCT07105735",
      "https://clinicaltrials.gov/study/NCT06976437",
      "https://clinicaltrials.gov/study/NCT06318533",
      "https://clinicaltrials.gov/study/NCT06469190",
      "https://clinicaltrials.gov/study/NCT06613490",
      "https://clinicaltrials.gov/study/NCT06337474"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-06T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 17
  },
  {
    "account_name": "Genmab",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.553857905208773,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "ACTIVE_NOT_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy i | trial_collaborator: Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | trial_collaborator: Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma",
    "best_fit_trial_title": "Epcoritamab-CAR T Cells for Large B-cell Lymphomas",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06458439",
    "best_urgency_trial_title": "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome",
    "best_urgency_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04623541",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Genmab",
    "total_score": 20.553857905208773,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04623541",
      "https://clinicaltrials.gov/study/NCT05660967",
      "https://clinicaltrials.gov/study/NCT05180474",
      "https://clinicaltrials.gov/study/NCT05852717",
      "https://clinicaltrials.gov/study/NCT06672705",
      "https://clinicaltrials.gov/study/NCT06536049",
      "https://clinicaltrials.gov/study/NCT05206357",
      "https://clinicaltrials.gov/study/NCT06458439"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 18
  },
  {
    "account_name": "Beijing Immunochina Medical Science & Technology Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.553857904418845,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07406984",
    "best_urgency_trial_title": "Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07406984",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Beijing Immunochina Medical Science & Technology Co., Ltd.",
    "total_score": 20.553857904418845,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07406984",
      "https://clinicaltrials.gov/study/NCT06886919",
      "https://clinicaltrials.gov/study/NCT06852573",
      "https://clinicaltrials.gov/study/NCT06718738",
      "https://clinicaltrials.gov/study/NCT06690359",
      "https://clinicaltrials.gov/study/NCT06691308",
      "https://clinicaltrials.gov/study/NCT06412458",
      "https://clinicaltrials.gov/study/NCT04440436"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 19
  },
  {
    "account_name": "Shanghai Xiniao Biotech Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.553857903270817,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases | trial_collaborator: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases | trial_collaborator: Universal Chimeric Antigen Receptor T-Cell \uff08UCAR T-cell\uff09 Therapy Targeting CD19/B Cell Maturation Antigen \uff08CD1",
    "best_fit_trial_title": "UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07410377",
    "best_urgency_trial_title": "CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07315087",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Shanghai Xiniao Biotech Co., Ltd.",
    "total_score": 20.553857903270817,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07410377",
      "https://clinicaltrials.gov/study/NCT07315087",
      "https://clinicaltrials.gov/study/NCT06939166",
      "https://clinicaltrials.gov/study/NCT06941129",
      "https://clinicaltrials.gov/study/NCT07155369",
      "https://clinicaltrials.gov/study/NCT06920433",
      "https://clinicaltrials.gov/study/NCT06933563",
      "https://clinicaltrials.gov/study/NCT06920446"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 20
  },
  {
    "account_name": "Nanjing Legend Biotech Co.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.542418422165376,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases | trial_collaborator: A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | trial_collaborator: A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus",
    "best_fit_trial_title": "A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06869278",
    "best_urgency_trial_title": "A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07331272",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Nanjing Legend Biotech Co.",
    "total_score": 20.542418422165376,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07331272",
      "https://clinicaltrials.gov/study/NCT07095075",
      "https://clinicaltrials.gov/study/NCT07049081",
      "https://clinicaltrials.gov/study/NCT06869278",
      "https://clinicaltrials.gov/study/NCT06313957",
      "https://clinicaltrials.gov/study/NCT06653556",
      "https://clinicaltrials.gov/study/NCT06395870",
      "https://clinicaltrials.gov/study/NCT06494371"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-02T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 21
  },
  {
    "account_name": "AbbVie",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.540375003749354,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and | trial_collaborator: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",
    "best_fit_trial_title": "MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06414148",
    "best_urgency_trial_title": "Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT04872790",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "AbbVie",
    "total_score": 20.540375003749354,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04623541",
      "https://clinicaltrials.gov/study/NCT04872790",
      "https://clinicaltrials.gov/study/NCT03933735",
      "https://clinicaltrials.gov/study/NCT05660967",
      "https://clinicaltrials.gov/study/NCT05753501",
      "https://clinicaltrials.gov/study/NCT07097363",
      "https://clinicaltrials.gov/study/NCT07197307",
      "https://clinicaltrials.gov/study/NCT06672705"
    ],
    "score_details": {
      "trial_count": 8,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-10T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 22
  },
  {
    "account_name": "Gracell Biotechnologies (Shanghai) Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.53043573097238,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: GC012F Injection in Refractory Idiopathic Inflammatory Myopathy | trial_collaborator: This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary  | trial_collaborator: GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)",
    "best_fit_trial_title": "Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07250269",
    "best_urgency_trial_title": "A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06235229",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Gracell Biotechnologies (Shanghai) Co., Ltd.",
    "total_score": 20.53043573097238,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06235229",
      "https://clinicaltrials.gov/study/NCT07086404",
      "https://clinicaltrials.gov/study/NCT06530849",
      "https://clinicaltrials.gov/study/NCT07250269",
      "https://clinicaltrials.gov/study/NCT07249879",
      "https://clinicaltrials.gov/study/NCT07058298",
      "https://clinicaltrials.gov/study/NCT07072884",
      "https://clinicaltrials.gov/study/NCT06880354"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-22T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 23
  },
  {
    "account_name": "Merck Sharp & Dohme LLC",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.512633841365776,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukem | trial_collaborator: Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | trial_collaborator: Her2-BATS and Pembrolizumab in Metastatic Breast Cancer",
    "best_fit_trial_title": "Pembro Plus CAR T-cell Therapy in R/R in PMBCL",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05934448",
    "best_urgency_trial_title": "A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05458297",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Merck Sharp & Dohme LLC",
    "total_score": 20.512633841365776,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05458297",
      "https://clinicaltrials.gov/study/NCT06395103",
      "https://clinicaltrials.gov/study/NCT07194980",
      "https://clinicaltrials.gov/study/NCT07227597",
      "https://clinicaltrials.gov/study/NCT04201873",
      "https://clinicaltrials.gov/study/NCT03272334",
      "https://clinicaltrials.gov/study/NCT05934448",
      "https://clinicaltrials.gov/study/NCT04920617"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 24
  },
  {
    "account_name": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.49922349186338,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia",
    "best_fit_trial_title": "Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "NA",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06871644",
    "best_urgency_trial_title": "PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07188610",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "PersonGen BioTherapeutics (Suzhou) Co., Ltd.",
    "total_score": 20.49922349186338,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07338604",
      "https://clinicaltrials.gov/study/NCT07312630",
      "https://clinicaltrials.gov/study/NCT07188610",
      "https://clinicaltrials.gov/study/NCT06092047",
      "https://clinicaltrials.gov/study/NCT06871644",
      "https://clinicaltrials.gov/study/NCT06417398",
      "https://clinicaltrials.gov/study/NCT06361745",
      "https://clinicaltrials.gov/study/NCT06279026"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-14T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 25
  },
  {
    "account_name": "Takeda",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.49915094714656,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | trial_collaborator: IVIG for Infection Prevention After CAR-T-Cell Therapy | trial_collaborator: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi",
    "best_fit_trial_title": "IVIG for Infection Prevention After CAR-T-Cell Therapy",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05952804",
    "best_urgency_trial_title": "A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05748197",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Takeda",
    "total_score": 20.49915094714656,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05748197",
      "https://clinicaltrials.gov/study/NCT06980480",
      "https://clinicaltrials.gov/study/NCT05952804",
      "https://clinicaltrials.gov/study/NCT03263572",
      "https://clinicaltrials.gov/study/NCT04464200",
      "https://clinicaltrials.gov/study/NCT05020015",
      "https://clinicaltrials.gov/study/NCT05757700"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-10T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 26
  },
  {
    "account_name": "Nanjing IASO Biotechnology Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.491643204309163,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies | trial_collaborator: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia | trial_collaborator: Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)",
    "best_fit_trial_title": "Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07055724",
    "best_urgency_trial_title": "IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07309900",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Nanjing IASO Biotechnology Co., Ltd.",
    "total_score": 20.491643204309163,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07309900",
      "https://clinicaltrials.gov/study/NCT06743503",
      "https://clinicaltrials.gov/study/NCT06464991",
      "https://clinicaltrials.gov/study/NCT07055724",
      "https://clinicaltrials.gov/study/NCT05219721",
      "https://clinicaltrials.gov/study/NCT05759793",
      "https://clinicaltrials.gov/study/NCT06902844",
      "https://clinicaltrials.gov/study/NCT04561557"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-12T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 27
  },
  {
    "account_name": "Nanjing Bioheng Biotech Co., Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.46431817651763,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases | trial_collaborator: CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia | trial_collaborator: RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies",
    "best_fit_trial_title": "Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06775912",
    "best_urgency_trial_title": "CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06622694",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Nanjing Bioheng Biotech Co., Ltd.",
    "total_score": 20.46431817651763,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06775912",
      "https://clinicaltrials.gov/study/NCT07337785",
      "https://clinicaltrials.gov/study/NCT07203404",
      "https://clinicaltrials.gov/study/NCT07142161",
      "https://clinicaltrials.gov/study/NCT06622694",
      "https://clinicaltrials.gov/study/NCT06548607",
      "https://clinicaltrials.gov/study/NCT06732492"
    ],
    "score_details": {
      "trial_count": 7,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-02T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 28
  },
  {
    "account_name": "Hebei Taihe Chunyu Biotechnology Co., Ltd",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.412544238059283,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human  | trial_collaborator: CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | trial_collaborator: Autologous Transplantation Combined With BCMA CAR-T in the Treatment of Young NDMM",
    "best_fit_trial_title": "Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",
    "best_fit_trial_status": "NOT_YET_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07259070",
    "best_urgency_trial_title": "Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07259070",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Hebei Taihe Chunyu Biotechnology Co., Ltd",
    "total_score": 20.412544238059283,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07259070",
      "https://clinicaltrials.gov/study/NCT07249073",
      "https://clinicaltrials.gov/study/NCT07169500",
      "https://clinicaltrials.gov/study/NCT07117305",
      "https://clinicaltrials.gov/study/NCT07109323",
      "https://clinicaltrials.gov/study/NCT05618041",
      "https://clinicaltrials.gov/study/NCT05388695",
      "https://clinicaltrials.gov/study/NCT07008872"
    ],
    "score_details": {
      "trial_count": 12,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2025-12-02T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 29
  },
  {
    "account_name": "Autolus Limited",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.398462215343162,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",
    "best_fit_trial_title": "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
    "best_fit_trial_status": "ACTIVE_NOT_RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04404660",
    "best_urgency_trial_title": "A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07400029",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Autolus Limited",
    "total_score": 20.398462215343162,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07400029",
      "https://clinicaltrials.gov/study/NCT06333483",
      "https://clinicaltrials.gov/study/NCT04404660",
      "https://clinicaltrials.gov/study/NCT07053800",
      "https://clinicaltrials.gov/study/NCT06173518"
    ],
    "score_details": {
      "trial_count": 5,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-10T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 30
  },
  {
    "account_name": "Bellicum Pharmaceuticals",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.37650347978633,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer | trial_collaborator: Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | trial_collaborator: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refract",
    "best_fit_trial_title": "Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "EARLY_PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT05620342",
    "best_urgency_trial_title": "Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06096038",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bellicum Pharmaceuticals",
    "total_score": 20.37650347978633,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT05620342",
      "https://clinicaltrials.gov/study/NCT06096038",
      "https://clinicaltrials.gov/study/NCT03016377",
      "https://clinicaltrials.gov/study/NCT02414269",
      "https://clinicaltrials.gov/study/NCT03721068"
    ],
    "score_details": {
      "trial_count": 5,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-05T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 31
  },
  {
    "account_name": "iCell Gene Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.372240932759322,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia  | trial_collaborator: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myel | trial_collaborator: CD4CAR for CD4+ Leukemia and Lymphoma",
    "best_fit_trial_title": "Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06197672",
    "best_urgency_trial_title": "Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06197672",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "iCell Gene Therapeutics",
    "total_score": 20.372240932759322,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06197672",
      "https://clinicaltrials.gov/study/NCT06071624",
      "https://clinicaltrials.gov/study/NCT03829540",
      "https://clinicaltrials.gov/study/NCT07328581",
      "https://clinicaltrials.gov/study/NCT04162353",
      "https://clinicaltrials.gov/study/NCT06787989"
    ],
    "score_details": {
      "trial_count": 6,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-22T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 32
  },
  {
    "account_name": "Allogene Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.37218732998655,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07085104",
    "best_urgency_trial_title": "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07085104",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Allogene Therapeutics",
    "total_score": 20.37218732998655,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07085104",
      "https://clinicaltrials.gov/study/NCT06500273",
      "https://clinicaltrials.gov/study/NCT04696731",
      "https://clinicaltrials.gov/study/NCT04416984",
      "https://clinicaltrials.gov/study/NCT04093596"
    ],
    "score_details": {
      "trial_count": 5,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-04T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 33
  },
  {
    "account_name": "Juventas Cell Therapy Ltd.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.370563400358606,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma | trial_collaborator: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure \u22653 Lines of Therapy. | trial_collaborator: Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute ",
    "best_fit_trial_title": "Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06676982",
    "best_urgency_trial_title": "Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06676982",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Juventas Cell Therapy Ltd.",
    "total_score": 20.370563400358606,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07275736",
      "https://clinicaltrials.gov/study/NCT06676982",
      "https://clinicaltrials.gov/study/NCT07265206",
      "https://clinicaltrials.gov/study/NCT07091370",
      "https://clinicaltrials.gov/study/NCT05667506",
      "https://clinicaltrials.gov/study/NCT06826430",
      "https://clinicaltrials.gov/study/NCT06231368",
      "https://clinicaltrials.gov/study/NCT06316791"
    ],
    "score_details": {
      "trial_count": 9,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2025-12-18T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 34
  },
  {
    "account_name": "Bioray Laboratories",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.351110209329367,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "trial_collaborator: Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC | trial_collaborator: Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. | trial_collaborator: Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC",
    "best_fit_trial_title": "Universal CAR-T Cell Therapy for MM",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "NA",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT07248176",
    "best_urgency_trial_title": "The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT05741359",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Bioray Laboratories",
    "total_score": 20.351110209329367,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT07248176",
      "https://clinicaltrials.gov/study/NCT07248163",
      "https://clinicaltrials.gov/study/NCT05741359",
      "https://clinicaltrials.gov/study/NCT06895811",
      "https://clinicaltrials.gov/study/NCT06485232",
      "https://clinicaltrials.gov/study/NCT06633042",
      "https://clinicaltrials.gov/study/NCT06681337",
      "https://clinicaltrials.gov/study/NCT05988216"
    ],
    "score_details": {
      "trial_count": 10,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2025-12-01T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 35
  },
  {
    "account_name": "A2 Biotherapeutics Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.34813257413112,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04981119",
    "best_urgency_trial_title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06051695",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "A2 Biotherapeutics Inc.",
    "total_score": 20.34813257413112,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT04981119",
      "https://clinicaltrials.gov/study/NCT06051695",
      "https://clinicaltrials.gov/study/NCT06682793",
      "https://clinicaltrials.gov/study/NCT05736731"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 36
  },
  {
    "account_name": "Poseida Therapeutics, Inc.",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.348132572921124,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06014762",
    "best_urgency_trial_title": "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06014762",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Poseida Therapeutics, Inc.",
    "total_score": 20.348132572921124,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06014762",
      "https://clinicaltrials.gov/study/NCT05239143",
      "https://clinicaltrials.gov/study/NCT04960579",
      "https://clinicaltrials.gov/study/NCT03741127"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 37
  },
  {
    "account_name": "Cartesian Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.34813256689145,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "NOT_YET_RECRUITING in high urgency phase (PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE3",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06799247",
    "best_urgency_trial_title": "Descartes-08 in Autoantibody Myositis",
    "best_urgency_trial_status": "NOT_YET_RECRUITING",
    "best_urgency_trial_phase": "PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT07391605",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Cartesian Therapeutics",
    "total_score": 20.34813256689145,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06799247",
      "https://clinicaltrials.gov/study/NCT07391605",
      "https://clinicaltrials.gov/study/NCT06038474",
      "https://clinicaltrials.gov/study/NCT04146051"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-13T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 38
  },
  {
    "account_name": "Cabaletta Bio",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.344851810536714,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1,PHASE2)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1,PHASE2",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT04422912",
    "best_urgency_trial_title": "RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1,PHASE2",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06359041",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Cabaletta Bio",
    "total_score": 20.344851810536714,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06359041",
      "https://clinicaltrials.gov/study/NCT04422912",
      "https://clinicaltrials.gov/study/NCT06121297",
      "https://clinicaltrials.gov/study/NCT07006805",
      "https://clinicaltrials.gov/study/NCT06154252",
      "https://clinicaltrials.gov/study/NCT06328777"
    ],
    "score_details": {
      "trial_count": 6,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-01-15T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 39
  },
  {
    "account_name": "Fate Therapeutics",
    "fit": 5.0,
    "urgency": 3.0,
    "access": 0.0,
    "total": 20.339118038186662,
    "fit_reason": "CAR-T trial",
    "urgency_reason": "RECRUITING in high urgency phase (PHASE1)",
    "urgency_source": "clinicaltrials",
    "trigger_summary": "",
    "best_fit_trial_title": "FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",
    "best_fit_trial_status": "RECRUITING",
    "best_fit_trial_phase": "PHASE1",
    "best_fit_trial_url": "https://clinicaltrials.gov/study/NCT06241456",
    "best_urgency_trial_title": "A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",
    "best_urgency_trial_status": "RECRUITING",
    "best_urgency_trial_phase": "PHASE1",
    "best_urgency_trial_url": "https://clinicaltrials.gov/study/NCT06308978",
    "sec": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "patents": {
      "recent_total": 0,
      "matched_total": 0,
      "matched_keywords": [],
      "examples": [],
      "most_recent_recent": null,
      "most_recent_matched": null
    },
    "target_roles": [
      "Clinical Scientist / Early Clinical Development Lead (Phase 1)",
      "Director/VP, Translational Medicine (Oncology/Immunology)",
      "Head/Director, Clinical Biomarkers / Translational Biomarkers",
      "Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core",
      "Director, Bioassay / Potency / Analytical Development"
    ],
    "company": "Fate Therapeutics",
    "total_score": 20.339118038186662,
    "fit_score": 5.0,
    "urgency_score": 3.0,
    "access_score": 0.0,
    "evidence_links": [
      "https://clinicaltrials.gov/study/NCT06308978",
      "https://clinicaltrials.gov/study/NCT07216105",
      "https://clinicaltrials.gov/study/NCT04629729",
      "https://clinicaltrials.gov/study/NCT06241456"
    ],
    "score_details": {
      "trial_count": 4,
      "sec_matched": 0,
      "patent_matched": 0,
      "most_recent_trial_update": "2026-02-11T00:00:00+00:00",
      "most_recent_other_matched": null
    },
    "rank": 40
  }
]